Concarlo Therapeutics

Executive Summary

Concarlo Therapeutics is a private, early-stage biotechnology company headquartered in San Francisco, focused on developing novel small molecule therapies for drug-resistant cancers. The company leverages world-leading innovation in p27 biology, a key tumor suppressor protein involved in cell cycle regulation, to create transformative treatments aimed at dramatically improving outcomes for cancer patients. Founded in 2021, Concarlo has not disclosed its total funding or valuation, indicating it is likely in preclinical or early clinical development. The company's platform targets mechanisms of drug resistance, a major challenge in oncology, and has the potential to address significant unmet medical needs, particularly in metastatic breast cancer as highlighted by its partnership with the FORCE Family organization. However, given its early stage and limited public information, the risk profile remains high, and its success will depend on advancing its pipeline through preclinical validation and clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead p27-Targeting Program30% success
• H1 2027Series A Financing Announcement50% success
• Q2 2027Partnership or Collaboration for Drug-Resistant Indications40% success